Clinical Trials Logo

Clinical Trial Summary

Purpose to evaluate the effects of intramuscular 17-Alpha-Hydroxyprogesterone Caproate (17-OHPC) for prevention of Emergent Cesarean Delivery in symptomatic Pregnant Women with Placenta Previa


Clinical Trial Description

Most authors report an increased risk of bleeding with advancing gestation among women with placenta previa.

The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) both recommend the use of 17-OHPC to prevent recurrent spontaneous preterm birth.

Preterm deliveries account for 75% of perinatal mortality and surviving preterm infants are at risk for neurological, respiratory, and gastrointestinal complications. So, it is therefore very important to try to prolong the pregnancy without increasing the risk of emergent delivery in cases with placenta previa. The authors hypothesized that a pharmacological strategy like 17-alpha-Hydroxyprogesterone caproate may improve pregnancy outcomes and may also allow obstetricians to tailor their approach to save delayed scheduled cesarean section women with a placenta previa.

The aim of this study to evaluate the role of17-alpha-Hydroxyprogesterone caproate in the prevention of preterm cesarean delivery (CD) in cases with symptomatic placenta previa with avoids of an emergent CD which affects the maternal outcome and prevents prematurity which affects the prenatal outcome. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03779438
Study type Interventional
Source Aswan University Hospital
Contact hany f sallam
Phone 01022336052
Email hany.farouk@aswu.edu.eg
Status Recruiting
Phase N/A
Start date January 1, 2019
Completion date March 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04518150 - Combined Bilateral Uterine Artery Ligation and Bakri Balloon During Cesarean Section N/A
Recruiting NCT04518163 - Bakri Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa N/A
Recruiting NCT03638024 - Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .
Terminated NCT01996345 - Vaginal Pessary Versus Expectant Management for Placenta Previa N/A
Recruiting NCT04609527 - Management of Placenta Accreta Spectrum Phase 2/Phase 3
Completed NCT03431116 - Low Implanted Second Trimester Placenta and Placenta Previa N/A
Completed NCT03321435 - The Placenta Previa and Fetal Weight N/A
Enrolling by invitation NCT05529381 - Anxiety and Depressive Symptoms in Placenta Previa / Accreta
Completed NCT04264234 - Management Of Placenta Previa Cases And Determination Of Hospitalization Criteria N/A
Completed NCT05340205 - Blood Loss During Cesarean Delivery in Placenta Previa Patients Phase 4
Completed NCT03570723 - Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa N/A
Completed NCT05283122 - Mostafa Maged Technique to Control and Prevent the Post-Partum Bleeding From the Lower Uterine Segment in Placenta Previa Cases N/A
Withdrawn NCT01442207 - Cerclage for Prevention on Preterm Birth in Women With Placenta Previa Phase 3
Not yet recruiting NCT03451136 - Cervical Length in Cases of Placenta Previa N/A
Completed NCT02966197 - Efficacy of Prophylactic Internal Iliac Artery Balloon Catheterization in the Management of Placenta Previa and Accreta N/A
Recruiting NCT02590484 - The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta N/A
Recruiting NCT05802251 - Sonographic Parameters and Risk of Antepartum Hemorrhage in Asymptomatic Women With Placenta Previa: A Cohort Study
Completed NCT03542552 - Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa Phase 3
Recruiting NCT03124472 - Effect of Uterine Artery Ligation Prior to Uterine Incision in Women With Placenta Previa N/A
Recruiting NCT03633175 - Progesterone in Patients With Placenta Previa Phase 2